Treatment of nonpsychotic relatives of patients with schizophrenia: Four case studies

Biological Psychiatry

Volumn 45, Issue 11, 1999, Pages 1412-1418

  Tsuang, Ming T ^a,b,c,d,e   Stone, William S ^a,b   Seidman, Larry J ^a,b,c,d   Faraone, Stephen V ^a,b,c,d   Zimmet, Suzanna ^a,b   Wojcik, Joanne ^a,b   Kelleher, James P ^a,b   Green, Alan I ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Commonwealth Research Center at MMHC ^*  (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Harvard Inst Psychiat E   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Attention; Genetics; Negative symptoms; Neuropsychology; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CASE REPORT; CLINICAL TRIAL; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; LONG TERM MEMORY; MALE; MENTAL FUNCTION; NEGATIVE SYNDROME; NEUROPSYCHOLOGY; PRIORITY JOURNAL; RELATIVE; SCHIZOPHRENIA; SIDE EFFECT; VERBAL MEMORY; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; VOLITION;

EID: 0032860273     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00364-3     Document Type: Article

References (30)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS). 1983;The University of Iowa, Iowa City.
2. Carpenter W.T., Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Patient response and resource management another view of clozapine treatment of schizophrenia . Am J Psychiatry. 152:1995;827-832.
3. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics effects on neuropsychological function in chronic schizophrenic patients . Schizophr Bull. 16:1990;477-499.
4. Chapman L.J., Chapman J.P. The measurement of differential deficit. J Psychiatric Res. 14:1978;303-311.
5. Cornblatt B.A., Keilp J.G. Genetics and the pathophysiology of schizophrenia. Schizophr Bull. 20:1994;31-46.
6. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The Continuous Performance Test, Identical Pairs verstion (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 26:1988;223-238.
7. Davis J.M., Janicak P.G. Risperidone a new, novel (and better?) antipsychotic . Psychiatr Ann. 26:1996;78-87.
8. Faraone SV, Green AI, Seidman LJ, Tsuang MT (1999): Clinical implications of schizotaxia: A new direction for research. Schizophr Bull, in press.
9. Faraone S.V., Seidman L.J., Kremen W.S., Pepple J.R., Lyons M.J., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients A diagnostic efficiency analysis . J Abnorm Psychol. 104:1995;286-304.
10. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT (1998): Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a four-year follow-up study. J Abnorm Psychol, in press.
11. Green A.I., Schildkraut J.J. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiatry. 3:1995;1-9.
12. Green M.F., Marshall B.D. Jr, Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am J Psychiatry. 154:1997;799-804.
13. Green M.F., Nuechterlein K.H., Breitmeyer B. Backward masking performance in unaffected siblings of schizophrenic patients. Arch Gen Psychiatry. 54:1997;465-472.
14. Hymowitz P., Frances A., Jacobsberg L.B., Sickles M., Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry. 27:1986;267-271.
15. Kremen W.S., Seidman L.J., Pepple J.R., Lyons M.J., Tsuang M.T., Faraone S.V. Neuropsychological risk indicators for schizophrenia a review of family studies . Schizophr Bull. 20:1994;103-119.
16. Marder S., Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
17. Meehl P.E. Schizotaxia, schizotypy, schizophrenia. Am Psychologist. 17:1962;827-838.
18. Meehl P.E. Schizotaxia revisited. Arch Gen Psychiatry. 46:1989;935-944.
19. Rossi A., Mancini F., Stratta P., Mettei P., Gismondi R., Pozzi F., et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia an open study . Acta Psychiatr Scand. 95:1997;40-43.
20. Seidman L.J. Clinical neuroscience and epidemiology in schizophrenia. Harv Rev Psychiatry. 3:1997;338-342.
21. Seidman L.J., Breiter H., Goodman J.M., Goldstein J.M., Woodruff P., O'Craven K., et al. A functional magnetic resonance imaging study of auditory vigilance with low and high information processing demands. Neuropsychology. 12:1998;505-518.
22. Seidman L.J., Faraone S.V., Goldstein J.M., Goodman J.M., Kremen W.S., Matsuda G., et al. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients a pilot magnetic resonance imaging study . Am J Med Gen (Neuropsychiatric Genetics). 74:1997;507-514.
23. Seidman L.J., Goldstein J.M., Breiter H.C., Goodman J.M., Ward M., Woodruff P., et al. Functional MRI of attention in relatives of schizophrenic patients. Schizophr Res. 24:1997;172.
24. Seidman L.J., Oscar-Berman M., Kalinowski A.G., Ajilor O., Kremen W.S., Faraone S.V., et al. Experimental and clinical neuropsychological measures of prefrontal dysfunction in schizophrenia. Neuropsychology. 9:1995;1-10.
25. Stip E., Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 41:(Suppl 2):1996;35S-40S.
26. Tamminga C.A. The promise of new drugs for schizophrenia treatment. Can J Psychiatry. 42:1997;265-273.
27. Tsuang M.T. Genotypes, phenotypes and the brain a search for connections in schizophrenia . Br J Psychiatry. 163:1993;299-307.
28. Tsuang M.T., Gilbertson M.W., Faraone S.V. Genetic transmission of negative and positive symptoms in the biological relatives of schizophrenics. Marneros A., Tsuang M.T., Andreasen N. Positive vs. Negative Schizophrenia. 1991;265-291 Springer-Verlag, New York.
29. Voglmaier M.M., Seidman L.J., Salisbury D., McCarley R.W. Neuropsychological dysfunction in schizotypal personality disorder a profile analysis . Biol Psychiatry. 41:1997;530-540.
30. Wyatt R.J. Early intervention for schizophrenia can the course of the illness be altered? Biol Psychiatry. 38:1995;1-3.